Teva leads way with a rival to US Uceris

Teva has become the first company to secure approval for, and to introduce ‘at risk’, a generic rival to Valeant’s Uceris (budesonide) 9mg extended-release tablets in the US. Citing Iqvia data for the 12 months ended May 2018, the Israeli firm said the branded treatment for ulcerative colitis had annual US sales of US$196 million.